Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations: A retrospective, multicentre, cross-sectional study

Clinical Drug Investigation

Volumn 28, Issue 12, 2008, Pages 767-776

  Denis, Philippe ^a,b   Lafuma, Antoine ^a,b   Jeanbat, Viviane ^a,b   Laurendeau, Caroline ^a,b   Berdeaux, Gilles ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CEMKA EVAL   (France)

^c Alcon France   (France)

Author keywords

Fixed combinations; Glaucoma; Intraocular pressure; Latanoprost timolol, therapeutic use; Ocular hypertension; Research and development; Travoprost timolol, therapeutic use

Indexed keywords

LATANOPROST PLUS TIMOLOL; TIMOLOL PLUS TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG INSTILLATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; CLOPROSTENOL; CROSS-SECTIONAL STUDIES; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; TIMOLOL;

EID: 55849095133     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200828120-00004     Document Type: Article

References (25)

1. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England and Wales. BMC Public Health 2006; 6: 58
2. Iwase A, Araie M, Tomidokoro A, et al. and the Tajimi Study Group. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology 2006; 113: 1354-62
3. Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 2006; 113: 1134, e1-1134. e1-11
4. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS). The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40
5. Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003; 121: 48-56
6. Whitson JT. Glaucoma. A review of adjunctive therapy and new management strategies. Expert Opin Pharmacother 2007; 8: 3237-49
7. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006; 22: 971-6
8. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144: 533-40
9. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005; 112: 863-8
10. EPARs for authorised medicinal products for human use: Duotrav [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/duotrav/ duotrav.htm [Accessed 2008 Nov 4]
11. EPARs for authorised medicinal products for human use: Ganfort [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/ganfort/ ganfort.htm [Accessed 2008 Nov 4]
12. Vidal. Ed Vidal. Paris, 2007
13. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007; 24: 1007-16
14. Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007; 17: 183-90
15. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004 Jan; 26 (1): 84-91
16. Nordmann JP, Berdeaux G. Use of Bayesian networks to predict the nocturnal intraocular pressure peak from day-time measurements. Clin Ther 2007; 29: 1751-60
17. Garcia-Feijoo J, Martinez de la Casa JM, Castillo A, et al. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 2006; 22: 1689-97
18. Association des Epidemiologistes de Langue Francaise. Déontologie et bonnes pratiques en epidemiologie, recommandations de l'association des epidémiologistes de langue francaise. Paris: Imprimerie Graphie Rouvet, 1998
19. Newgard CD, Hedges HR, Arthur M, et al. Advanced statistics: the propensity score. A method for estimating treatment effect in observational research. Acad Emerg Med 2004; 11: 953-61
20. Konstas AG, Nakos E, Tersis I, et al. A comparison of once daily morning vs evening dosing of concomitant latanoprost/ timolol. Am J Ophthalmol 2002 Jun; 133 (6): 753-7
21. Denis Ph, Launois R, Devaux M, et al. Comparison of diurnal intraocular pressure control by latanoprost versus travoprost: results of an observational survey. Clin Drug Invest 2006; 26: 703-14
22. Payet S, Denis Ph, Berdeaux G, et al. Assessment of the cost-effectiveness of travoprost versus latanoprost as single agents for glaucoma treatment in France. Clin Drug Invest 2008; 28 (3): 183-98
23. Kaback M, Geanon J, Katz G, et al. START Study Group. Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr Med Res Opin 2004; 20: 1341-5
24. Pajic B, Conductors of the Swiss COSOPT Survey (CSCS). Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices. Curr Med Res Opin 2003; 19: 95-101
25. Javitt J, Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. J Glaucoma 2000; 9: 398-408